Healthier Populations, Everywhere

We are value driven, not just in the sense of the values we adhere to, but also in the solutions we offer. We provide informed advice and services along the entire life cycle of products and health programmes - from upstream development to downstream programmes, including the surveillance of diseases within communities, policy making, and the forecasting of vaccine supply.


  • Africa
  • Americas
  • Europe
  • Oceania
  • Albania
  • Armenia
  • Bangladesh
  • Barbados
  • Belarus
  • Benin
  • Bosnia and Herzegovina
  • Brazil
  • Bulgaria
  • Cambodia
Focus Areas
Projects - Focus Areas
  • Access
  • Evaluation
  • Implementation
  • Policy & Strategy
Vaccine Preventable Diseases
Projects - Vaccine Preventable Diseases
  • Cholera
  • COVID-19
  • Diphtheria
  • Enteric Fever
  • Human Papillomavirus
  • Influenza
  • Japanese Encephalitis
  • Leishmaniasis
  • Measles-Rubella
  • Meningitis
Projects - Clients
  • Asian Development Bank
  • Bill & Melinda Gates Foundation
  • Centers for Disease Control and Prevention (CDC)
  • Christian Medical College
  • Coalition for Epidemic Preparedness Innovation (CEPI)
  • EU Commission
  • Gavi, The Vaccine Alliance (Gavi)
  • Global Task Force on Cholera Control (GTFCC)
  • Inter American Development Bank
  • ISGlobal
Sort By (Projects)
  • Focus Project
2022 — 2023

Tuberculosis vaccine market analysis

Evaluate the viability and impact of investment in the clinical development of a new TB vaccine.

Wellcome Trust
Image Credit: Helena Spongenberg
  • Focus Project
2020 — 2021

Development of the European Immunisation Agenda 2030

Development of the European regional adaptation of the global vision and strategies for immunization for the period 2021-2030.

World Health Organisation (WHO)
Image Credit: CDC
  • Focus Project
  • New Format
2019 — 2020

Develop a business case for a macrofilaricide as part of onchocerciasis treatment and control

Development of a business case for the use of macrofilaricide drugs to control onchocerciasis.

Bill & Melinda Gates Foundation
Image Credit: IOC/Fiocruz/Gutemberg Brito
  • New Format
2017 — 2018

Develop a business case for a schistosomiasis vaccine

Development of a business case for investment and further development of a schistosomiasis vaccine.

Bill & Melinda Gates Foundation
2023 — Ongoing

Develop a business case for new treatments for onchocerciasis and lymphatic filariasis

Establishing the business case for investment in new drugs to treat the neglected tropical diseases onchocerciasis and lymphatic filariasis.

Bill & Melinda Gates Foundation
Image Credit: MMGH/Carsten Mantel
2019 — Ongoing

Advocacy for the Vaccine Against Invasive non-typhoidal Salmonella (Vacc-iNTS) project

MMGH is part of the Vaccine Against Invasive non-typhoidal Salmonella (Vacc-iNTS) consortium, made up of 12 partners from eight different countries including three disease-endemic countries. The initiative advances the development of an iNTS vaccine by conducting a Phase I clinical study in Europe and Africa. The project, funded by the European Union’s Horizon 2020 Research and Innovation Programme, will investigate the immunogenicity and safety of a iNTS-GMMA vaccine. As part of this effort MMGH will focus on strengthening a collaborative network to enhance disease awareness and drive vaccine advocacy.

EU Commission
2019 — 2023

Definition and market sizing of the use cases for micro-array patches for Measles-Rubella vaccine

MMGH supports the WHO’s Vaccine Product & Delivery Research department in defining and sizing (including a demand forecast) the use cases for a Measles Rubella vaccine micro-array patch (MAP). The use cases and their market sises are assessed and validated via expert consultation across a broad group of stakeholders, including country programme managers, global experts, and pharmaceutical and development agencies. The approach and methodology was validated by the WHO Immunisation and Vaccines Related Implementation Research Advisory Committee (IVIR-AC), Measles-Rubella MR-MAP Working group, and the Market for Information to Access Advisory Group. The project is now focusing on further understanding self-administration of MR-MAPs and will be extended to include MMR-MAPs. The project will help the WHO in better aligning MAP product development efforts to the measles-rubella control and implementation needs and the Gavi Vaccine Innovation Prioritisation Strategy (VIPS).

World Health Organisation (WHO)
2021 — 2021

Market analysis on COVID-19 vaccine regional self-sufficiency for Asian countries 

Testing regional self-sufficiency for access to the COVID-19 vaccine in Asia. 

Asian Development Bank
Image Credit: CDC
2019 — 2021

Demand forecast and financial sustainability analysis for a group B streptococcal vaccine

MMGH supported the WHO Initiative for Vaccine Research (IVR) in developing a variety of forecast scenarios for the demand of a group B streptococcal (GBS) vaccine administered through maternal immunisation. The forecast was validated by an Expert Advisory Group. Based on the potential vaccine profiles, MMGH assessed the financial viability of the vaccine for a prospective developer. The output of the work will inform the WHO Public Health Value Proposition and contribute to advocacy efforts aimed at supporting the creation of a healthy market for the vaccine.

World Health Organisation (WHO)
2019 — 2020

Operationalisation of group B streptococcal maternal vaccination

MMGH supported the WHO Initiative for Vaccine Research (IVR) in preparing a report on the considerations for operationalising group B streptococcal (GBS) maternal vaccination as part of a Public Health Value Proposition for GBS vaccines. The report was developed on the basis of an extensive literature review and an online survey gathering information on global and country stakeholder perceptions on GBS disease, its public health importance, and the prioritisation of GBS vaccination as a means to reduce its impact.

World Health Organisation (WHO)
Image Credit: Lorenzo Pezzoli
2018 — 2018

Development of the Oral Cholera Vaccine preferred product characteristics

MMGH supported the WHO Initiative for Vaccine Research (IVR) in updating the Preferred Product Characteristics for the Oral Cholera Vaccine. MMGH facilitated the expert meeting and coordinated the drafting of the final document providing updated guidance to vaccine developers consistent with the strategic axes of the new Cholera Roadmap.

World Health Organisation (WHO)